Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1985 1
1986 2
1988 1
1990 2
1995 1
1996 1
1997 1
1998 1
2000 1
2001 1
2004 1
2006 2
2007 2
2008 3
2009 6
2010 3
2012 2
2013 2
2014 1
2015 2
2018 1
2019 1
2020 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

36 results

Results by year

Filters applied: . Clear all
Page 1
Ruxolitinib treatment for myelofibrosis: Efficacy and tolerability in routine practice.
Ellis MH, Lavi N, Mishchenko E, Dally N, Lavie D, Courevitch A, Gutwein O, Bulvik S, Braester A, Chubar E, Tavor S, Duek A, Kirgner I, Koren-Michowitz M. Ellis MH, et al. Among authors: bulvik s. Leuk Res. 2015 Aug 12:S0145-2126(15)30356-8. doi: 10.1016/j.leukres.2015.08.003. Online ahead of print. Leuk Res. 2015. PMID: 26364797
Thymic involution, a co-morbidity factor in amyotrophic lateral sclerosis.
Seksenyan A, Ron-Harel N, Azoulay D, Cahalon L, Cardon M, Rogeri P, Ko MK, Weil M, Bulvik S, Rechavi G, Amariglio N, Konen E, Koronyo-Hamaoui M, Somech R, Schwartz M. Seksenyan A, et al. Among authors: bulvik s. J Cell Mol Med. 2010 Oct;14(10):2470-82. doi: 10.1111/j.1582-4934.2009.00863.x. J Cell Mol Med. 2010. PMID: 19650830 Free PMC article.
Bone marrow blast elimination by the fifth day of 7 + 3 induction is the strongest predictor of potential cure in patients with acute myeloid leukemia younger than 61 years of age: A long-term follow-up of a multi-center prospective study.
Ofran Y, Hayun M, Leiba R, Zuckerman T, Horowitz N, Hoffman R, Ringelstein S, Lavi N, Frisch A, Henig I, Gatt ME, Hellmann I, Arad A, Bulvik S, Ram R, Gino-Moor S, Saban R, Tvito A, Rowe JM, Ganzel C. Ofran Y, et al. Among authors: bulvik s. Am J Hematol. 2020 Jan;95(1):E3-E5. doi: 10.1002/ajh.25651. Epub 2019 Oct 17. Am J Hematol. 2020. PMID: 31591736 Free article. No abstract available.
Primary plasma cell leukemia in the era of novel agents for myeloma - a multicenter retrospective analysis of outcome.
Ganzel C, Rouvio O, Avivi I, Magen H, Jarchowsky O, Herzog K, Cohen Y, Tadmor T, Horwitz NA, Leiba M, Nagler A, Cohen Y, Bulvik S, Polliack A, Rowe JM, Gatt ME; Israeli Multiple Myeloma Study Group. Ganzel C, et al. Among authors: bulvik s. Leuk Res. 2018 May;68:9-14. doi: 10.1016/j.leukres.2018.02.010. Epub 2018 Mar 2. Leuk Res. 2018. PMID: 29501828
Current clinical uses of intravenous immunoglobulin.
Shimoni Z, Bulvik S, Niveni M. Shimoni Z, et al. Among authors: bulvik s. Clin Med (Lond). 2006 Nov-Dec;6(6):621; author reply 621-2. doi: 10.7861/clinmedicine.6-6-621. Clin Med (Lond). 2006. PMID: 17228565 Free PMC article. No abstract available.
36 results